Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

被引：0
|
作者：
Ghobrial, Irene M. [1 ]
Banwait, Ranjit [1 ]
Azab, Abdel Kareem [1 ]
Phong Quang [1 ]
Laubach, Jacob P. [1 ]
Donovan, Amanda [1 ]
Bagshaw, Meghan [1 ]
Armand, Philippe [2 ]
Munshi, Nikhil C. [1 ]
Schlossman, Robert L. [1 ]
Chuma, Stacey [1 ]
Kunsman, Janet [1 ]
Warren, Diane [1 ]
Anderson, Kenneth C. [1 ]
Richardson, Paul G.
机构：
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：817 / 818
页数：2
相关论文
共 50 条
  • [1] Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma
    Ghobrial, Irene
    Azab, Abdel Kareem A.
    Laubach, Jacob P.
    Banwait, Ranjit
    Rourke, Meghan
    Quang, Phong
    Munshi, Nikhil C.
    Schlossman, Robert L.
    Chuma, Stacey
    Kunsman, Janet
    Warren, Diane
    Sam, Amy
    Still, Eric
    Morgan, Brittany
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2010, 116 (21) : 809 - 810
  • [2] Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma
    Ghobrial, Irene M.
    Laubach, Jacob P.
    Shain, Kenneth H.
    Baz, Rachid
    Boswell, Erica N.
    Henrick, Patrick M.
    Azab, Abdel Kareem
    Hanlon, Courtney
    Chuma, Stacey
    Leblebjian, Houry
    Noonan, Kimberly
    MacNabb, Megan H.
    Warren, Diane
    Armand, Philippe
    Paba-Prada, Claudia E.
    Munshi, Nikhil C.
    Schlossman, Robert L.
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2014, 124 (21)
  • [3] Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma
    Ghobrial, Irene M.
    Shain, Kenneth
    Hanlon, Courtney
    Banwait, Ranjit
    Azab, Abdel Kareem
    Laubach, Jacob P.
    Armand, Philippe
    Munshi, Nikhil C.
    Schlossman, Robert L.
    Chuma, Stacey
    Boswell, Erica N.
    Mostyn, Patrick
    Houry, Leblebjian
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2013, 122 (21)
  • [4] Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma
    Ghobrial, Irene M.
    Liu, Chia-Jen
    Zavidij, Oksana
    Azab, Abdel K.
    Baz, Rachid
    Laubach, Jacob P.
    Mishima, Yuji
    Armand, Philippe
    Munshi, Nikhil C.
    Basile, Frank
    Constantine, Michael
    Vredenburgh, James
    Boruchov, Adam
    Crilley, Pamela
    Henrick, Patrick M.
    Hornburg, Kalvis T. V.
    Leblebjian, Houry
    Chuma, Stacey
    Reyes, Kaitlen
    Noonan, Kimberly
    Warren, Diane
    Schlossman, Robert
    Paba-Prada, Claudia
    Anderson, Kenneth C.
    Weller, Edie
    Trippa, Lorenzo
    Shain, Kenneth
    Richardson, Paul G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (11) : 1244 - 1253
  • [5] Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
    Ghobrial, Irene M.
    Shain, Kenneth H.
    Laubach, Jacob
    Henrick, Patrick
    Vredenburg, James
    Crilley, Pamela
    Constantine, Michael
    Block, Caroline
    Basile, Frank G.
    Cappuccio, Joseph
    Azab, Abdel Kareem
    Lai, Emily
    Caola, Aaron
    Banwait, Ranjit
    Savell, Alexandra
    Munshi, Nikhil C.
    Paba-Prada, Claudia E.
    Schlossman, Robert L.
    Chuma, Stacey
    Noonan, Kimberly
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2015, 126 (23)
  • [6] Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
    Richardson, Paul G.
    Weller, Edie
    Jagannath, Sundar
    Avigan, David E.
    Alsina, Melissa
    Schlossman, Robert L.
    Mazumder, Amitabha
    Munshi, Nikhil C.
    Ghobrial, Irene M.
    Doss, Deborah
    Warren, Diane L.
    Lunde, Laura E.
    McKenney, Mary
    Delaney, Carol
    Mitsiades, Constantine S.
    Hideshima, Teru
    Dalton, William
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5713 - 5719
  • [7] Phase I trial of bortezomib and Samarium Sm 153 lexidronam in refractory and relapsed multiple myeloma
    Berenson, James R.
    Patel, Ravi
    Yellin, Ori
    Swift, Regina A.
    CANCER INVESTIGATION, 2007, 25 : 33 - 33
  • [8] Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma
    Roccaro, A. M.
    Leduc, R.
    Nelson, M.
    Sam, A.
    Chuma, S.
    Colson, K.
    O'Connor, K.
    Ghobrial, I. M.
    Munshi, N. C.
    Schlossman, R.
    Harris, B.
    Warren, D.
    Dollard, A. M.
    Laubach, J.
    Vij, R.
    Campagnaro, E.
    Birner, A.
    Dixon-Lipscomb, V.
    Anderson, K. C.
    Richardson, P. G.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S86 - S86
  • [9] Bortezomib in Relapsed/Refractory Multiple Myeloma
    Shen, Z.
    Wang, L.
    Yan, H.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S62 - S62
  • [10] Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
    San-Miguel, Jesus F.
    Richardson, Paul G.
    Guenther, Andreas
    Sezer, Orhan
    Siegel, David
    Blade, Joan
    LeBlanc, Richard
    Sutherland, Heather
    Sopala, Monika
    Mishra, Kaushal K.
    Mu, Song
    Bourquelot, Priscille M.
    Victoria Mateos, Maria
    Anderson, Kenneth C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) : 3696 - +
12345